Warsh Is a Hawk in Dove's Clothing, Yardeni Says

Warsh Is a Hawk in Dove's Clothing, Yardeni Says Warsh Is a Hawk in Dove's Clothing, Yardeni Says Ed Yardeni of Yardeni Reseach says Federal Reserve Chairman Kevin Warsh "pretty much" committed to bringing inflation down to 2%. Yardeni talks about what Warsh will do now on "Bloomberg Surveillance." -------- More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9 Visit http://www.bloomberg.com for business news & analysis, up-to-the-minute market data, features, profiles and more. Connect with Bloomberg Television on: X: https://twitter.com/BloombergTV Facebook: https://www.facebook.com/BloombergTelevision Instagram: https://www.instagram.com/bloombergtv/ Connect with Bloomberg Business on: X: https://twitter.com/business Facebook: https://www.facebook.com/bloombergbusiness Instagram: https://www.instagram.com/bloombergbusiness/ TikTok: https://www.tiktok.com/@bloombergbusiness?lang=en Reddit: https://www.reddit.com/r/bloomberg/ LinkedIn: https://www.linkedin.com/company/bloomberg-news/ More from Bloomberg: Bloomberg Radio: https://twitter.com/BloombergRadio Bloomberg Surveillance: https://twitter.com/bsurveillance Bloomberg Politics: https://twitter.com/bpolitics Bloomberg Originals: https://twitter.com/bbgoriginals Watch more on YouTube: Bloomberg Technology: https://www.youtube.com/@BloombergTechnology Bloomberg Originals: https://www.youtube.com/@business Bloomberg Quicktake: https://www.youtube.com/@BloombergQuicktake Bloomberg Espanol: https://www.youtube.com/@bloomberg_espanol Bloomberg Podcasts: https://www.youtube.com/@BloombergPodcasts Mike Reed of RBC said by their account, inflation was mentioned by Kevin Walsh 19 times Look. When the payroll numbers came out real real strong, we we kinda reiterated our position surprised me is how hawkish that came across. If the Fed were in a position where

Geopolitical escalation risk in the Middle East (Iran/Red Sea) is supporting oil prices and can spill into defense, shipping, and inflation expectations. Separately, tech momentum persists (AI hardware demand cited via SMCI), and industrial aerospace cycle commentary (GE). Policy risks include potential new tariffs aimed at generic drug manufacturers. Japan yen weakness and South Korea market controls are notable for FX/EM positioning but are less directly tradable from this snippet alone.

Key market-relevant items: (1) JPY falls past 163 per USD to a fresh ~40-year low, with commentary implying BOJ policy lacks credibility; Japan trade deficit widens as weak yen and Iran-war-related energy costs inflate imports. (2) Trump signals a 100% tariff on generic drugs starting Aug 2028 (very long lead time, but it raises reshoring/US capacity optionality). (3) China introduces broad state support to arrest a tech-stock selloff (near-term sentiment backstop for China internet/tech). (4) Nikkei reports TSMC may raise chip prices by up to ~10% in 2027 (upstream pricing power vs. downstream margin pressure). (5) Iran-war spillover risk remains elevated (energy/risk-off sensitivity).

US officials are downplaying prospects for Iran talks; discussion highlights a flare-up tied to the Strait of Hormuz control/access, with mediators (Qatar/Pakistan) trying to de-escalate. Key market implication is elevated geopolitical risk premia around oil supply/transit through Hormuz, with knock-on effects to energy, shipping (tankers), defense, and oil-sensitive transport/consumer sectors.

Trump said generic drug manufacturers will have two years to move production to the US or face a 100% import tariff starting in 2028. If implemented, this would materially raise the cost of imported generics and could incentivize US onshoring/US-based capacity additions, while pressuring foreign-heavy generic suppliers and downstream pharmacy/wholesaler margins (unless pricing is passed through). Key uncertainty is political/legal feasibility and whether it becomes actual policy vs campaign posture.

Bloomberg segment flags multiple policy/geopolitical catalysts: the US is ramping up scrutiny/pressure on Chinese AI developers (likely regulatory and export-control adjacent), Trump threatens tariffs on generic drug imports, and regional geopolitics (Iran conflict; South China Sea tensions) remains elevated. Market color includes chip volatility, an Asia tech-led rally, and yen weakness with possible Japan policy response. A specific corporate headline: Topsports tumbles after Nike ends a China partnership; Beijing is said to be stepping up efforts to stabilize tech stocks. Overall, actionable via sector/ETF exposures (AI/chips, China tech, generics/pharma supply chain, oil/defense, JPY hedges), but details are high level (no concrete rule text, dates, or scope).

Discussion centers on the widening Iran war, its stated ~$37.5B cost to the US so far, political pressure over additional defense spending, escalation risk around the Strait of Hormuz/Red Sea shipping lanes (including talk of more bombing/occupation scenarios), and separate comments on the need for AI safeguards/regulation. Market-relevant angles are (1) higher near-term US defense outlays and replenishment demand, (2) energy/shipping risk premia if Hormuz/Red Sea disruptions intensify, (3) risk-off/airline margin pressure from higher jet fuel, and (4) headline risk for AI regulation (less immediately tradable from this snippet).

Bloomberg “The Close” episode framed a late-day market narrative around (1) a rebound gathering pace in chipmakers/AI spend, (2) the idea that value stocks and financials may be underappreciated beneficiaries of AI capex, (3) company-specific updates including Amazon Business scale, GM raising outlook despite tariffs, and (4) notable movers/laggards (Danaher, Schwab, Super Micro) plus a near-term Tesla earnings preview. The source is light on hard numbers, so actionability is mainly thematic/sector-tilt rather than single-name catalyst trading (except TSLA earnings setup and GM outlook headline).

Bloomberg Businessweek Daily discusses: (1) President Trump threatening 50% tariffs on Canadian goods, likely invoking an obscure 1930 trade law and facing legal challenges; (2) ongoing US-Iran conflict implications for global costs and risks in the Strait of Hormuz; (3) Charles Schwab reporting better-than-expected Q2 earnings with record daily average revenue trades; (4) concern about declining US biotech investment while China and others increase focus, featuring Cytokinetics CEO.